Medicines for treating diabetes and heart disease affected by price negotiations

The Biden administration says Medicare beneficiaries will save about $1.5 billion in out-of-pocket costs for drugs used to treat diabetes, heart disease, arthritis and other conditions through new prices negotiated with drug companies that will take effect in 2026.

The savings range from 79 percent for Januvia, used to treat diabetes, to 38 percent for Imbruvica, used to treat blood cancer. These are the cost of the drug before discounts or rebates, not the price patients actually pay for their prescriptions.

A look at the drugs and the negotiated prices.

Januvia

• Manufacturer: Merck Sharp Dohme
• Diseases: Diabetes
• Negotiated price: $113 for a 30-day supply
• Reduction: 79%

fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill:

• Manufacturer: Novo Norrodisk
• Diseases: Diabetes
• Negotiated price: $119 for a 30-day supply
• Reduction: 76%

Farxiga

• Manufacturer: AstraZeneca AB.
• Diseases: diabetes, heart failure and chronic kidney disease
• Negotiated price: $178.50 for a 30-day supply
• Reduction: 68%

Enbrel

• Manufacturer: Immunex Corp.
• Diseases: Rheumatoid arthritis, psoriasis and psoriatic arthritis
• Negotiated price: $2,355 for a 30-day supply
• Reduction: 67%

Jardiance

• Manufacturer: Boehringer Ingelheim
• Diseases: diabetes, heart failure and chronic kidney disease
• Negotiated price: $197 for a 30-day supply
• Reduction: 66%

Stelara

• Manufacturer: Janssen Biotech Inc.
• Diseases: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
• Negotiated price: $4,695 for a 30-day supply
• Reduction: 66%

Xarelto

• Manufacturer: Janssen Pharms
• Diseases: Prevention and treatment of blood clots. Risk reduction in patients with coronary or peripheral arterial disease
• Negotiated price: $197 for a 30-day supply
• Reduction: 62%

Eliquis

• Manufacturer: Bristol Myers Squibb
• Diseases: Prevention and treatment of blood clots
• Negotiated price: $231 for a 30-day supply
• Reduction: 56%

Entry

• Manufacturer: Novartis Pharms Corp
• Diseases: Heart failure
• Negotiated price: $295 for a 30-day supply
• Reduction: 53%

Imbruvica

• Manufacturer: Pharmacyclics LLC
• Diseases: Blood cancer
• Negotiated price: $9,319 for a 30-day supply
• Savings: 38%

Originally published: August 15, 2024 at 18:21